BCL6 and lymphoma: The authors performed structural studies (broad complex, Tramtrack, Bric-a-Brac) to find an appropriate Bcl6 BTB domain-binding compound BI-3802 that degraded Bcl6 in human GCB-type DLBCL lymphoma cell lines at nanomolar concentrations.